# A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)

> **NCT07444489** · PHASE3 · ENROLLING_BY_INVITATION · sponsor: **Biogen** · enrollment: 120 (estimated)

## Conditions studied

- Antibody-mediated Rejection

## Interventions

- **DRUG:** Felzartamab

## Key facts

- **NCT ID:** NCT07444489
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2026-04-16
- **Primary completion:** 2031-05-28
- **Final completion:** 2031-05-28
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07444489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07444489, "A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07444489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*